Aileron Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Rein Therapeutics

15/11/2024 14:07

* Aileron Therapeutics Inc  ALRN.OQ  reported a quarterly
adjusted
loss of 27 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -40 cents.  The lone analyst forecast for the
quarter was for a loss of 41 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Aileron Therapeutics Inc's reported EPS for the quarter
was a
loss of 27 cents​.
    * The company reported a quarterly loss of $5.85 million.
    * Aileron Therapeutics Inc shares had fallen by 6.5% this
quarter and gained 8.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Aileron
Therapeutics Inc is 13.00 
This summary was machine generated from LSEG data November 15 at
02:07 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.41          -0.27          Beat
 Jun. 30 2024      -0.42          -0.45          Missed
 Mar. 31 2024      -0.14          -0.86          Missed
 Dec. 31 2023      -0.16          -1.54          Missed